ESR introduction and
outline ESR Project 2
Born in 1996 in Barcelona, Spain. She obtained her bachelor’s degree in Biomedical Science at Autonomous University of Barcelona in 2018. During her bachelor’s degree, Alba participated in an Erasmus Exchange program. She spent 4 months in the University of Eastern Finland, where she enhanced its knowledge in regenerative medicine and in vivoimaging techniques. In the last period of her bachelor’s degree she developed her internship project in the Institute of Biotechnology and Biomedicine (IBB). There, she worked in Dr. Dolores Jaraquemada’s Laboratory of Cellular Immunology. Her project was based in the study of cellular stress as a mechanism of lipid neoantigens generation in human type 1 diabetes.
After obtaining her bachelor’s degree, Alba decided to focus her career towards the development and manufacture of novel drugs. Therefore, she coursed a master’s degree in Pharmaceutical and Biotechnology Industry in Pompeu Fabra University (UPF). In 2019 she developed her master’s thesis in Reig Jofre’s Laboratories company, placed in Barcelona, where she worked as a trainee fellow in the biotechnology department. Her research was based on the development and validation of a new analytical assay for Heparin Sodium using STA Compact Max® system and following European Pharmacopoeia guidelines.
Since January 2020 she works as a PhD student at Miltenyi Biotech, which is located close to Cologne, in Germany. There and in collaboration of The Medical School of Hannover, Alba is carrying out her project in the context of the H2020 TRAIN-HEART consortium. In particular her project aims at discovering new targets to prevent heart failure. She is going to compare diseased and healthy hearts by applying cutting edge technologies like 3D microscopy to identify important changes. The understanding of key differences between healthy and diseased hearts will be a major milestone in the development of new therapeutics that will be able to improve patients’ lives.
- Hannover Medical School (groups of Dr Bär and Prof. Thum, Institute of Molecular and Translational Therapeutic Strategies)
- Maastricht University (group of Prof. de Windt, molecular cardiology)